The fate of bone after renal transplantation

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 4, 1998, Pages 389-395

  Dissanayake, Imara R ^a   Epstein, Sol ^b,c  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Monroe Office Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AMYLOIDOSIS; BONE DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; OSTEODYSTROPHY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEROID THERAPY;

EID: 0031852253     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199807000-00007     Document Type: Review

References (83)

1. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996; 11:1-7.
2. Goodman WG, Cobum JW, Slatopolsky E, Salusky IB. Renal osteodystrophy in adults and children. In: Favus MJ (editor): Primer on the metabolic bone diseases and disorders of mineral metabolism. New York: Raven Press, 1996. pp. 341-360.
3. Hruska K, Teitelbaum S. Renal osteodystrophy. N Engl J Med 1995; 333:166-174.
4. Katz IA, Epstein S. Post-transplantation bone disease. J Bone Miner Res 1992; 7:123-126.
5. Dinarello C. Cytokines: agents provocateurs in hemodialysis? Kidney Int 1992; 41:683-694.
6. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interluekin-1 and tumor necrosis factor alpha. Kidney Int 1990; 37:116-125.
7. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39:954-960.
8. Mucsi I, Hercz G. Adynamic bone disease: pathogenesis. diagnosis and •• clinical relevance. Curr Opin Nephrol Hypertens 1997; 6:356-361 This is a recent comprehensive review of bone disease and includes pathogenesis, diagnosis and management of this complex entity.
9. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325:544-550.
10. Horber FF, Casez JP, Stelger U, Caerniack A, Montandon A, Jaeger PH. Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994; 9:1-9.
11. Pichetle V, Bonnardeauz A, Prudhomme L, Gagne M, Cardinal J. Ouimet D. Long term bone loss in kidney transplant recipients: a cross sectional and longitudinal study. Am J Kidney Dis 1996; 28:105-114.
12. Bagni B, Gilli P, Cavallini A, Bagni I, Marzola MC, Orzincolo C, Wahner HW. Continuing loss of vertebral mineral density in renal transplant recipients. Nuclear Med 1994; 21:108-112.
13. Grotz W, Mundinger A, Gugel B, Exner V, Kirste G, Schollmeyer J. Bone mineral density after kidney transplantation: a cross sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 1995; 59:982-986.
14. Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Schollmeyer PJ. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995; 10:2096-2100.
15. Torregrosa JV, Campistol JM, Montesinos B, Pons F, Martinez de Osaba MJ, Oppenheimer F. Factors involved in the loss of bone mineral density after renal transplantation. Transplant Proc 1995; 27:2224-2225.
16. Grotz WH, Mundinger FA, Muller CB, Rasenack J, Schulte-Monting J, • Langer MFJ, Schollmeyer PJ. Trabecular bone architecture in female renal allograft recipients assessed by computed tomography. Nephrol Dial Transplant 1997; 12:564-569. This study documents alteration of bone architecture with noninvasive computed tomography in renal transplant patients. These patients are compared with patients with osteoporosis who had similar BMDs.
17. Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. • Effects of three immunosuppressive regimens on vertebral bone density in renal transplantation recipients. Transplantation 1997; 63:380-386 This study reports that cyclosporine A did not cause lumbar bone loss. However, interpretation of this study is hampered by wide variation in Z scores and small sample numbers in the cyclosporine A monotherapy group.
18. Shane E, Epstein S. Immunosuppressive therapy and the skeleton. Trends Endocrinol Metab 1994; 5:169-175.
19. Boe J, Skoogh B-E. Is long-term treatment with inhaled steroids in adults hazardous? Eur Respir J 1992; 5:1037-1039.
20. Wolpaw T, Deal CL, Fleming-Brooks S, Bartucci MR, Schulak JA, Hricik D, Factors influencing vertebral bone density after renal transplantation. Transplantation 1994; 58:1186-1189.
21. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989; 4:137-141.
22. Canalis E. Mechanisms of glucocorticoid action in bone: implication to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996; 81:3441-3447.
23. Gennari C. Glucocorticoid induced osteoporosis. Clin Endocrinol 1994; 41:273-274.
24. Libanati CR, Baylink DJ. Prevention and treatment of glucocorticoid-induced osteoporosis. Chest 1992;102:1426-1435.
25. Lukert BP. Glucocorticoid-induced osteoporosis. South Med J 1992; 85:48-51.
26. Gronowicz GA, DeRome ME, McCarthy M-B. Glucocorticoids inhibit libronectin synthesis and messenger ribonucleic acid levels in cultured fetal rat parietal bones. Endocrinology 1991; 128:1107-1114.
27. Doherty WJ, DeRome ME, McCarthy M-B, Gronowicz GA. The effect of glucocorticoids on osteoblast function. J Bone Joint Surg 1995; 77-A:396-404.
28. Gohel AR, Hand AR, Gronowicz GA. Immunogold localization of β1-integrin in bone: effect of glucocorticoids and insulin-like growth factor I on integrins and osteocyte formation. J Histochem Cytochem 1995; 43:1085-1096.
29. Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Curr Opin Rheumatol 1995; 7:255-261.
30. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331:365-376
31. Charhon SA, Pierre PD, Malaval L, Chavassieux PM, Arlot M, Chapuy MC, Meunier PJ. Serum bone gla-bone protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 1986; 63:892-897.
32. Thiebaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26:549-555.
33. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Fracture frequency after kidney transplantation. Transplant Proc 1994; 26:1764.
34. Felson DT, Anderson JJ. A cross sectional study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1987; 1(8538):902-906.
35. Landmann J, Renner N, Gachter A, Thiel G, Harder F. Cyclosporin A and osteonecrosis of the femoral head. J Bone Joint Surg 1987; 69:1226-1228.
36. Coen G. Fracturing osteoporosis after kidney transplantation: what are the options? Nephrol Dial Transplant 1996; 11:567-569.
37. Gauthier VJ, Barbosa LM. Bone pain in transplant recipients responsive to calcium channel blockers. Ann Intern Med 1994; 121:863-865.
38. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123:2571-2577.
39. Buchinsky FJ, Ma Y, Mann GN, Rucinski B, Bryer HP, Romero DF, et al. T lymphocytes play a critical role in the development of cyclosporin A induced osteopenia. Endocrinology 1996; 137:2278-2285.
40. Stein B, Takizawa M, Schlosberg M, Movsowitz C, Fallon M, Berlin JA, Epstein S. Evidence that cyclosporine G is less deleterious to rat bone in vivo than cyclosporine A. Transplantation 1992; 53:628-632.
41. Stewart PJ, Stern PH. Cyclosporines: correlation of immunosuppressive activity and inhibition of bone resorption. Calc Tissue Int 1989; 45:222-226.
42. Orcel P, Denne MA, De Vernejoul MC. Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology 1991; 128:1638-1646.
43. Zahner M, Terzic F, Pacifici R. T-cells mediate a stimulatory effect of • cyclosporin A on human osteoclastogenesis while immature osteoclast precursors are directly regulated by glucocorticoids [abstract T38]. J Bone Miner Res 1997; 12 (suppl 1):S198. Although in abstract form, this study shows the importance of the T cell in mediating the bone effects of cyclosporine A.
44. Bourbigol B, Moal MC, Cledes J. Bone histology in renal transplant patients receiving cyclosporin [letter]. Lancet 1988; 1:1048-1049.
45. Aubia J, Masramon J, Serrano S, Lloveras J, Marinoso LL. Bone histology in renal transplant patients receiving cyclosporin [letter]. Lancet 1988; 1:1048
46. Dumoulin G, Hory B, Nguyen NU, Bresson C, Fournier V, Bouhaddi M, • et al. No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long term renal transplant recipients. Am J Kidney Dis 1997; 29:746-753. This cross sectional study documents biochemical evidence of persistent hyperparathyroidism with partial contribution to post-transplantation bone disease.
47. Thiebaud D, Krieg MA, Gillard-Berguer D, Jacquet F, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26:549-555.
48. Shane E, Del C, Rivas M, Silverberg SJ, Sook Kim T, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med 1993; 94:257-264.
49. Bryer HP, Isserow JA, Armstrong EC, Mann GN, Rucinski B, Buchinsky FJ, et al. Azathioprine alone is bone sparing and does not alter cyclosprin A induced osteopenia in the rat. J Bone Miner Res 1995; 10:132-138
50. Epstein S, Shane E. Transplantation osteoporosis. In: Marcus R. •• Feldman D, Kelsey J (editors): Osteoporosis, 1st ed. San Diego: Academic Press; 1996. pp. 947-957. This is an excellent book chapter reviewing immunosuppressive induced bone disease and clinical aspects of osteopenia after organ transplantation.
51. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WSS, Epstein S. The deleterious effects of long-term cyclosporine A, cyclosporine G and FK506 on bone mineral metabolism in vivo. Transplantation 1994; 57:1231-1237.
52. Romero DF, Buchinsky FJ, Rucinski B, Cvetkovic M, Bryer HP, Liang XG, et al. Rapamycin: a bone sparing immunosuppressant? J Bone Miner Res 1995; 10:760-768.
53. Dissanayake IR, Goodman GR, Bowman AR, Ma Y, Pun S, Jee WSS, Epstein S. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1997; 65:275-278.
54. Slatoposky E, Delmez J. Bone disease in chronic renal failure and after renal transplantation. In: Coe F, Favus M (editors): Disorders of bone and mineral metabolism, 1st Edn. New York: Raven Press; 1992. pp. 905-934.
55. Massari PU. Disorders of bone and mineral metabolism after renal •• transplantation. Kidney Int 1997; 52:1412-1421. This is a well done review on post-RTX bone mineral metabolism.
56. David-Neto E, Jorgetti V, Soeiro NMR, Pereira RC, Borelli A, lanhez LE, et al. Reversal of aluminum-related bone disease after renal transplantation. Am J Nephrol 1993; 13:12-17.
57. Briner VA, Thiel G, Monnier-Faugere MC, Bognar B, Landmann J, Kamber V, Maluche HH. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1.25 vitamin D levels two years after kidney transplantation. Transplantation 1995; 59:1393-1400.
58. Pietshmann P, Vychytil A, Woloszezuk W, Kovarik J. Bone metabolism in patients with functioning kidney grafts: increased serum levels of osteocalcin and parathyroid hormone despite normalization of kidney function. Nephron 1991; 59:533-536.
59. Korkor AB. Reduced binding of [3H] 1.25-dihydroxyvitamin D, in the parathyroid glands of patients with renal failure. N Engl J Med 1987; 316:1573-1577.
60. Drueke T. Nephrology forum: the pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48:259-272.
61. Moore L, Alloway R, Acchiardo S, Vera S, Shokough-Amiri M, Gaber A. Clinical observation of metabolic changes occurring in renal transplant recipients receiving ketoconazole. Transplantation 1996; 61:537-541.
62. Amado JA, Riancho JA, De Francisco ALM, Cotorruelo JG, Feijanes J, Arias M, et al. Hyperparathyroidism is responsible for the increased levels of osteocalcin in patients with normally functioning kidney grafts. Nephron 1989; 52:209-215.
63. Setterberg L, Sandberg J, Elinder CG, Nordenstrom J. Bone demineralization after renal transplantation: contribution of secondary hyperparathyroidism manifested by hypercalcemia. Nephrol Dial Transplant 1996; 11:1825-1828.
64. Dumoulin G, Hory B, Nguyen NU, Henriet MT, Bresson C, Regnard J, Saint-Hillier Y. Acute oral calcium load decreases parathyroid secretion and suppresses tubular phosphate loss in long-term renal transplant recipients. Am J Nephrol 1995; 15:238-244.
65. Felsenfeld A, Gutman R, Drezner M, Llach F. Hypophosphatemia in long term renal transplant recipients: effect on bone histology and 1.25-dihydroxycholecalciferol. Miner Electrolyte Metab 1986; 12:333-341.
66. Moorhead JF, Ahmed KY, Varghese Z, Will MR, Baillod RA, Tatler GL, Fairney A. Hypophosphatemic osteomalacia after cadaveric renal transplantation. Lancet 1974; 1:694-697.
67. Steiner RW, Ziegler M, Halasz NA, Catherwood BD, Manolagas S, Deftos L. Effect of daily oral vitamin D and calcium therapy, hypophosphatemia and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 1993; 56:843-846.
68. Koch KM. Nephrology forum: dialysis related amyloid. Kidney Int 1992; 41:1416-1429.
69. Jadoul M, Malchem J, Pirson Y, Maldague B, van Ypersele C. Effect of renal transplantation on the radiologic signs of dialysis amyloid osteoarthropathy. Clin Nephrol 1989; 32:194-197.
70. Tan S, Irish A, Winearls C, Brown E, Gower P, Clutterbuck E, et al. Long term effects of renal transplantation on dialysis-related amyloid deposits symptomatology. Kidney Int 1996; 50:282-289.
71. Bowman AR, Sass DA, Dissanayake IR, Ma YF, Liang H, Yuan Z, et al. The role of testosterone in cyclosporine-induced osteopenia. J Bone Miner Res 1997; 12:607-615.
72. Samojlik E, Kirschner A, Ribot S, Szmal E. Changes in the hypothalamic-pituitary-gonadal axis in men after cadaver kidney transplantation and cyclosporin therapy. Am Soc Androl 1991; 13:332-336.
73. Moe S. The treatment of steroid-induced bone loss in transplantation. •• Curr Opin Nephrol Hypertens 1997; 6:544-549. This is an excellent recent review of the management of steroid induced bone loss in transplant patients.
74. Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufilanchas JJ, Hawkins F. Calcitonin, etidronate and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 1997; 60:155-159.
75. Van Cleemput J, Daenen W, Geusens P, Dequeker P, Van De Werf F, VanHaecke J. Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Transplantation 1996; 61:1495-1499.
76. 3 and calcium in kidney transplant patients. Transplant Proc 1996; 28:3485-3487.
77. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. •• Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997; 337:382-387. A prospective randomized placebo-controlled trial of bisphosphonates in steroid-induced osteoporosis is presented.
78. Fan S, Almond MK, Ball E, Evans K, Cunningham J. Randomized •• prospective study demonstrating prevention of bone loss by pamidronate during the first year after renal transplantation [abstract]. J Am Soc Nephrol 1996; 7:1789. This is the first study, in abstract form, that successfully utilizes bisphosphonates in renal transplant patients.
79. Civitelli R, Calcitonin. In: Marcus R, Feldman D, Kelsey J (editors): Osteoporosis, 1st ed. San Diego, CA: Academic Press: 1996. pp. 1235-1253.
80. Montemurro L, Schiraldi G, Fraioli P, Rizzato G. Prevention of corticosteroids induced osteoporosis with salmon calcitonin. Calcif Tissue Int 1991; 49:71-76.
81. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid induced bone loss. J Bone Miner Res 1992; 7:1063-1069.
82. Gallagher JC. Estrogen: prevention and treatment of osteoporosis. In: Marcus R, Feldman D, Kelsey J (editors): Osteoporosis, 1st ed, San Diego, CA: Academic Press; 1996. pp. 1191-1204.
83. Hung CJ, Lee PC, Song CM, Chang YT, Tsai MT, Dai YS, et al. Clinical implication of hormone treatment in post menopausal kidney transplants. Transplant Proc 1996; 28:1548-1550.